Venus Remedies logo

Venus Remedies financials and balance sheet

NSE: VENUSREMBSE: 526953Pharmaceuticals & BiotechnologySmall Cap

Last close ₹1,404.30down ₹37.20 (2.58%)BSE ₹1,396.30

Share price at the NSE close on 23 Oct 2026. Previous close ₹1,441.50.

52-week range of traded prices to 23 Oct 2026
₹432.10Low, 31 Oct 2025₹2,044.30High, 29 Jun 2026
Market cap
₹1,877 Cr1,337th largest listed
P/E
16.2
P/B
2.8
Dividend yield
0.71%
ROE
19.0%
ROCE
21.1%
Debt to equity
0.00
Volume, NSE
52,800

10 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Venus Remedies annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
Peak revenue ₹769 Cr, year to Mar 2026A loss in 3 of the 10 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 0.6% of operating profit in the first full year.

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue769
  2. Materials and goods−387
  3. Employee costs−85
  4. Other expenses−153
  5. Operating profit144
  6. Depreciation−25
  7. Other income+11
  8. One-off items0.0
  9. Finance costs0.0
  10. Profit before tax131
  11. Tax−31
  12. Net profit99

What the company owns

  • Plant, investments and other assets₹528 Cr
  • Inventory₹129 Cr
  • Receivables₹116 Cr
  • Current investments₹74 Cr
  • Cash and bank₹28 Cr

What pays for it: net worth and liabilities

  • Net worth₹690 Cr
  • Owed to suppliers₹111 Cr
  • Other liabilities₹76 Cr

Profit and loss

Standalone, ₹ crore, years to March.Venus Remedies quarterly results

₹ croreMar 2017Mar 2018Mar 2019Filed 11 JunMar 2020Mar 2021Mar 2022Filed 8 JunMar 2023Filed 29 MayMar 2024Filed 6 AugMar 2025Filed 12 JunMar 2026Filed 26 May
Revenue from operations375355302322515575538575639769
300312268279468506476514569625
Materials and goods bought222205182177337376337352375387
Employee costs25–30––4452627285
Other expenses54–56––8787100122153
Operating profit before depreciation754434434769626170144
Operating margin20.0%12.3%11.4%13.4%9.1%12.0%11.4%10.6%10.9%18.7%
Materials, % of revenue59.0%–60.2%––65.4%62.6%61.2%58.6%50.4%
Employee costs, % of revenue6.7%–10.0%––7.6%9.7%10.8%11.3%11.0%
Other expenses, % of revenue14.3%–18.4%––15.1%16.3%17.4%19.1%19.9%
Depreciation and amortisation41333331343331262225
Operating profit after depreciation34111121336303548119
Other income115418810112111
Finance costs343525131300000
Profit before one-off items and tax1−23−1931845404769131
One-off items––−9−923000100
Profit before tax1−23−28−64145404779131
−43−12−13−41116–31
Net profit5−27−27−8544929315399
Other comprehensive income––0––00001
Total comprehensive income––−27––49293152100
Net margin1.3%−7.5%−9.0%−2.6%10.5%8.5%5.4%5.3%8.2%12.9%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the years to Mar 2018, Mar 2020 and Mar 2021 they do not, so they are left blank. Tax is left blank for the year to Mar 2025: profit before tax less the tax charge stated does not come to the profit after tax the same statement states, so the tax charge is not shown.
Earlier years, Mar 2008 to Mar 2016
₹ croreMar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016
Revenue from operations214265312357405461526452403
160202237275315343393365323
Materials and goods bought134167188204235273301264242
Operating profit before depreciation53637483911181338780
Operating margin24.9%23.7%23.9%23.2%22.4%25.7%25.3%19.2%19.8%
Depreciation and amortisation4412101032394540
Operating profit after depreciation495863738087954239
Other income200000011
Finance costs5914192624294137
Profit before one-off items and tax–49495555636623
One-off items–––––––3–
Profit before tax4649495555636653
Tax8487565–2
Net profit3946414750576151
Net margin18.0%17.2%13.2%13.3%12.3%12.4%11.6%1.0%0.3%
Standalone, ₹ crore, years to March.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Filed 11 JunMar 2020Mar 2021Mar 2022Filed 8 JunMar 2023Filed 29 MayMar 2024Filed 6 AugMar 2025Filed 12 JunMar 2026Filed 26 May
341––449478509590690
Share capital12––1313131313
Reserves329––436465495576676
225––39393900
254––837373105158
137––4758601828
Total assets732––579609641713876
479––314291280277470
254––264318361436406
Net debt224––−11−34−48−162−102
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017, Mar 2018, Mar 2020 and Mar 2021, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2022Filed 8 JunMar 2023Filed 29 MayMar 2024Filed 6 AugMar 2025Filed 12 JunMar 2026Filed 26 May
41283583151
412855103186
−29−35−151638
Receivables00−5−10−12
Inventories−24−24−4170
Payables00−61753
Other working capital−4−110−8−3
Tax paid00−15−18−34
Capital spending14891038
Free cash flow27202674113
−17−51−7−76−182
−9000−1
Dividends paid00000
Shares bought back00000
Shares issued00000
Net change in cash15−23287−32
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019, Mar 2020 and Mar 2021.

Per share

Standalone, ₹ per share, years to March.Venus Remedies dividend history

₹ per shareMar 2017Mar 2018Mar 2019Filed 11 JunMar 2020Mar 2021Mar 2022Filed 8 JunMar 2023Filed 29 MayMar 2024Filed 6 AugMar 2025Filed 12 JunMar 2026Filed 26 May
Earnings per share₹4.14−₹21.54−₹21.97−₹6.67₹43.97₹37.12–₹22.82₹39.32₹74.29
Diluted earnings per share₹4.14−₹21.54−₹21.97−₹6.67₹43.97₹37.12–₹22.82₹39.32₹74.29
Dividend per share–––––––––₹10.00
Book value per share––₹276.25––₹336.21₹357.63₹380.48₹440.91₹515.80
Dividend payout–––––––––13.5%
Shareholder yield–––––0.0%0.0%0.0%0.0%0.0%
Market cap at the year end (₹ crore)1128141273393612174364001,096
Earnings per share is left blank for the year to Mar 2023: the earnings per share stated does not match any profit the filing states over the shares in issue, and the share count barely moved during the period.

Ratios

Standalone, years to March.Venus Remedies PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Filed 11 JunMar 2020Mar 2021Mar 2022Filed 8 JunMar 2023Filed 29 MayMar 2024Filed 6 AugMar 2025Filed 12 JunMar 2026Filed 26 May
Revenue growth−6.8%−5.4%−15.0%6.8%59.6%11.8%−6.5%7.0%11.2%20.2%
Operating profit growth−5.7%−41.9%−21.3%25.6%8.8%46.9%−10.6%−1.1%15.0%105.6%
Net profit growth294.3%––––−9.7%−40.9%5.3%72.3%89.0%
Earnings per share growth294.3%––––−15.6%––72.3%88.9%
––−8.0%––10.9%6.2%6.2%9.6%15.5%
––––––−4.7 pts−0.1 pts3.4 pts6.0 pts
From the net margin––––––−4.0 pts−0.1 pts3.4 pts5.5 pts
From asset turnover––––––−0.6 pts0.1 pts0.2 pts0.4 pts
From borrowing––––––0.0 pts−0.1 pts−0.3 pts0.1 pts
Return on capital employed––0.2%––7.4%5.8%6.5%8.2%17.3%
Cash conversion–––––83.5%96.9%116.0%158.1%152.1%
Interest cover1.00.30.10.91.0–––––
Debt to equity––0.66––0.090.080.080.000.00
Receivable days––38––1958575755
Inventory days––283––12212312298122
Payable days––67––48534467104
Cash conversion cycle, days––254––931281358873
Working capital days––129––841171289669
Asset turnover––0.41––0.990.910.920.940.97
Assets per rupee of net worth––2.15––1.291.281.271.231.24
Sales per rupee of plant––1.68––4.164.414.835.766.97
Capital spending to depreciation–––––0.420.250.350.441.53
Plant being built, % of plant in use––35.9%––18.3%21.4%17.7%23.8%46.6%
No balance sheet is on record for the years to Mar 2017, Mar 2018, Mar 2020 and Mar 2021, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
12.5%
Cash from operations against operating profit
105.0%
Measure10 years5 years3 years
Revenue growth, yearly rate6.7%8.4%12.7%
Profit growth, yearly rate55.5%12.8%50.8%
Return on equity, average–9.7%10.4%
Return on capital employed, average–9.0%10.7%
Operating margin, average13.0%12.7%13.4%
Net margin, average3.3%8.1%8.8%
Asset turnover, average–0.950.94
Cash conversion cycle, days, average–10398
Debt to equity, average–0.050.03

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations339270151
Cash from investing−332−265−182
Cash from financing−11−1−1
Capital spending785638
Dividends paid000
Shares bought back000
Shares issued for cash000
Borrowings raised–00
Borrowings repaid000

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Effective tax ratePublished threshold 17.16 per cent−355.13–––––––––
A threshold marked as ours has no published figure; it is the line we read the check against.